Delivery Order SPE2DB22D2218-SPE2DB25FR2UB
- Not listed
- The Defense Logistics Agency awarded a $5,211.66 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Kerendia 10 mg tablets (90-count). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 29, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract, this delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $3,708.36 to AmerisourceBergen Drug Corp for Kerendia 10 mg tablets (30-count packages) on June 18, 2025, with completion targeted for June 20, 2025. This firm fixed price delivery order was competitively awarded without set-aside designation and is being fulfilled from the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Kerendia 10 mg tablets (30-count packages) with a ceiling value of $1,529.00. This is a firm fixed-price delivery order with no set-aside designation, representing a competitive award under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Kerendia 10 mg tablets (30-count units) with a ceiling value of $1,159.29. This firm fixed-price delivery order, which is set to be completed by August 29, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The contract involved no...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,430.52 for Kerendia 10 mg tablets (90-count packaging) on July 15, 2025, with an ultimate completion date of July 16, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $17,656.81 to AmerisourceBergen Drug Corp for the supply of Kerendia 10 mg tablets (30-count units) under a firm fixed price contract. The award, issued on August 19, 2025, with an ultimate completion date of August 20, 2025, represents a non-competitive delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. This...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,593.24 on August 20, 2025, for the supply of Kerendia 10 mg tablets (30-count packages). This firm fixed-price, non-set-aside contract is scheduled for completion by August 21, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. Kerendia is a prescription medication used in the treatment of chronic kidney disease, representing the type of...
- The Defense Logistics Agency awarded a delivery order valued at $1,135.08 to AmerisourceBergen Drug Corp for KERENDIA 20 MG tablets (30-count package) on September 3, 2025, with an ultimate completion date of September 4, 2025. This firm fixed-price contract, which was competitively awarded with no set-aside designation, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The place of performance is...
- The Defense Logistics Agency awarded a $8,996.13 delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Kerendia 20 mg tablets (30-count units). This firm fixed-price, competitively awarded contract is scheduled for completion by June 2, 2025, with performance at the vendor's Conshohocken, Pennsylvania location. The award represents a non-set-aside delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a $1,014.95 delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Kerendia 10 mg tablets (30-count units). This is a firm fixed price, non-set-aside contract with a completion date of September 12, 2025, and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- SPE2DB22D2218Indefinite Delivery Contract
- SPE2DB22D2218-SPE2DB25FR2UBDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 16, 2025, for the supply of Kerendia 10 mg tablets (30-count) with a ceiling value of $1,270.12. This competitively awarded, firm fixed-price delivery order is scheduled for completion by June 17, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as the primary vehicle for pharmaceutical supply to the Defense Health Agency and other federal healthcare systems. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, continues to fulfill essential medication needs for military and veteran healthcare systems through its extensive portfolio with the Defense Logistics Agency. As one of multiple prime vendors under the DLA's pharmaceutical supply framework, the company supplies a comprehensive range of brand-name and generic medications, including specialty pharmaceuticals across multiple therapeutic domains. This delivery order for Kerendia—a treatment for chronic kidney disease—exemplifies the company's ongoing role in supporting federal healthcare procurement through competitively awarded, fixed-price transactions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 6/16/25 |